Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2019, Article ID 2546161, 25 pages
https://doi.org/10.1155/2019/2546161
Review Article

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Correspondence should be addressed to Huiqun Ma; nc.ude.utjx.liam@nuqiuham

Received 26 October 2018; Revised 10 January 2019; Accepted 14 February 2019; Published 10 September 2019

Academic Editor: Jacek Tabarkiewicz

Copyright © 2019 Fan Bai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Fan Bai, Gang Gang Li, Qingmin Liu, Xinwu Niu, Ruilian Li, and Huiqun Ma, “Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials,” Journal of Immunology Research, vol. 2019, Article ID 2546161, 25 pages, 2019. https://doi.org/10.1155/2019/2546161.